Towa Pharmaceutical Co., Ltd.
4553.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥65,327,000 | ¥65,149,000 | ¥65,857,000 | ¥70,333,000 |
| % Growth | 0.3% | -1.1% | -6.4% | – |
| Cost of Goods Sold | ¥41,796,000 | ¥41,474,000 | ¥41,872,000 | ¥44,503,000 |
| Gross Profit | ¥23,531,000 | ¥23,675,000 | ¥23,985,000 | ¥25,830,000 |
| % Margin | 36% | 36.3% | 36.4% | 36.7% |
| R&D Expenses | ¥0 | ¥0 | ¥3,512,000 | ¥5,292,000 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥18,294,000 | ¥18,468,000 | ¥19,354,000 | ¥12,440,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥1,000 | -¥3,512,000 | ¥0 |
| Operating Expenses | ¥18,294,000 | ¥18,469,000 | ¥19,354,000 | ¥17,732,000 |
| Operating Income | ¥5,237,000 | ¥5,206,000 | ¥4,631,000 | ¥8,098,000 |
| % Margin | 8% | 8% | 7% | 11.5% |
| Other Income/Exp. Net | ¥2,758,000 | -¥1,246,000 | -¥132,000 | ¥3,433,000 |
| Pre-Tax Income | ¥7,995,000 | ¥3,960,000 | ¥4,499,000 | ¥11,531,000 |
| Tax Expense | ¥2,294,000 | ¥1,447,000 | ¥136,000 | ¥3,463,000 |
| Net Income | ¥5,701,000 | ¥2,513,000 | ¥4,362,000 | ¥8,069,000 |
| % Margin | 8.7% | 3.9% | 6.6% | 11.5% |
| EPS | 115.81 | 51.05 | 88.61 | 163.92 |
| % Growth | 126.9% | -42.4% | -45.9% | – |
| EPS Diluted | 115.81 | 51.05 | 88.61 | 163.92 |
| Weighted Avg Shares Out | 49,228 | 49,227 | 49,227 | 49,227 |
| Weighted Avg Shares Out Dil | 49,228 | 49,227 | 49,227 | 49,227 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥91,000 | ¥61,000 | ¥53,000 | ¥50,000 |
| Interest Expense | ¥609,000 | ¥540,000 | ¥465,000 | ¥386,000 |
| Depreciation & Amortization | ¥5,657,000 | ¥5,249,000 | ¥5,337,000 | ¥5,162,000 |
| EBITDA | ¥14,259,000 | ¥10,456,000 | ¥9,320,000 | ¥17,080,000 |
| % Margin | 21.8% | 16% | 14.2% | 24.3% |